10-Q: TransCode Therapeutics Reports First Quarter 2024 Results, Faces Nasdaq Delisting Risk

TransCode Therapeutics reported a net loss of $3.3 million for the first quarter of 2024 and is facing potential delisting from the Nasdaq Capital Market.

Summary

• TransCode Therapeutics reported a net loss of approximately $3.3 million for the three months ended March 31, 2024, compared to a net loss of $4.8 million for the same period in 2023.
• The company's cash balance was approximately $4.9 million as of March 31, 2024.
• Operating expenses totaled approximately $3.3 million for the quarter, with research and development expenses at $1.8 million and general and administrative expenses at $1.5 million.
• The company believes its current cash will fund operations into the third quarter of 2024, but additional capital will be required to continue operations beyond that point.
• TransCode is facing potential delisting from the Nasdaq Capital Market due to not meeting the minimum bid price requirement, and a hearing is scheduled for June 25, 2024.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive developments in clinical trials and collaborations, but the financial situation and potential delisting from Nasdaq are significant concerns. The overall sentiment is negative due to the financial risks and uncertainty.

Positives

• The company has made progress in its clinical trial programs, including receiving FDA approval to proceed with a Phase I/II clinical trial for TTX-MC138.
• TransCode has entered into a collaboration agreement with Debiopharm to develop new targeted nucleic acid delivery modalities.
• The company has submitted SBIR applications to the National Cancer Institute for funding of TTX-MC138 and TTX-siPDL1 clinical development.

Negatives

• The company experienced a net loss of $3.3 million for the first quarter of 2024.
• The company's cash balance of $4.9 million is only expected to fund operations into the third quarter of 2024.
• TransCode is facing potential delisting from the Nasdaq Capital Market due to not meeting the minimum bid price requirement.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is a risk of delisting from the Nasdaq Capital Market, which could negatively impact the company's stock price and ability to raise capital.
• The company is subject to the risks associated with any early-stage biopharmaceutical company, including the uncertainty of research and development success and regulatory approvals.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to inaccurate financial reporting.
• The company is dependent on third parties for clinical trials and manufacturing, which could lead to delays or other issues.

Future Outlook

The company plans to expand development of its lead therapeutic candidate and other candidates, and explore strategic partnerships. Management believes that current cash is sufficient to fund operations and capital requirements into the third quarter of 2024, but does not believe that existing cash will be sufficient to fund requirements for a full 12 months from the date of these financial statements. The company will require additional capital to support its planned expanded operations.

Management Comments

• Management believes that current cash is sufficient to fund operations and capital requirements into the third quarter of 2024.
• The company plans to expand development of its lead therapeutic candidate and other candidates, and explore strategic partnerships.

Industry Context

The company is operating in the competitive and rapidly changing biopharmaceutical industry, specifically in the area of RNA therapeutics and oncology. The company's focus on targeted delivery mechanisms is aligned with a key challenge in the industry. The collaboration with Debiopharm highlights the industry trend of partnerships to advance drug development.

Comparison to Industry Standards

• The company's cash burn rate is typical for an early-stage biotech company, but the need for additional capital is a common challenge.
• The company's focus on RNA therapeutics is aligned with a growing trend in the industry, with companies like Moderna and BioNTech demonstrating the potential of this approach.
• The company's proprietary TTX delivery platform is a differentiator, as many competitors rely on lipid particles or chemical structures for delivery.
• The company's clinical trial progress is comparable to other companies in the early stages of drug development, but the potential delisting from Nasdaq is a significant concern.
• The company's collaboration with Debiopharm is similar to other partnerships in the industry, where companies combine their expertise to accelerate drug development.

Management Changes

Legal Proceedings

• The company is currently disputing a claim by an investment bank that it is entitled to fees.

Stakeholder Impact

• Shareholders face the risk of significant dilution and potential loss of investment due to the need for additional capital and the risk of delisting.
• Employees may be impacted by potential cost reduction strategies, including further headcount reductions.
• Customers and partners may be impacted by potential delays or changes in the company's development programs.

Next Steps

• The company will continue to advance its clinical trial programs, including the Phase I/II trial for TTX-MC138.
• The company will continue to explore strategic partnerships and collaborations.
• The company will seek additional funding through equity, debt, and grants.
• The company will appeal the Nasdaq delisting determination at a hearing on June 25, 2024.

Key Dates

Keywords

biopharmaceutical, oncology, RNA therapeutics, clinical trials, TTX-MC138, Nasdaq delisting, microRNA-10b, capital raise, research and development, financial results